Sandoz

For Cheryl, access led to a moment she had never experienced before. Two days after starting treatment, she was able to hold her husband’s hand without pain for the first time in their relationship. It was a simple moment. But for Cheryl, it meant so much more. Watch her story: https://lnkd.in/eHvGgqit #WithPatientsInMind #PioneeringAccess

Cheryl believes access starts with the right information. As a patient advocate, Cheryl fights misinformation around patents and biosimilar medicines so people can have informed conversations about their care. Discover why accurate information matters to Cheryl: https://lnkd.in/eHvGgqit #WithPatientsInMind #PioneeringAccess

What can more affordable medicines mean for everyday healthcare? The simple answer: a world of difference. Biosimilars can substantially broaden access to biologic medicines and support more affordable healthcare systems. Healthcare professionals bring a practical perspective to this discussion, drawing on their work with patients. 📽️ Explore the role of biosimilars in cancer care through an oncologist’s eyes. #GlobalBiosimilarsWeek

For Global Biosimilars Week, I’ve been reflecting on what it takes to turn the promise of biosimilars into real impact for patients. The answer starts long before a medicine reaches the market. Over the past few months, we've celebrated three important milestones expanding our end-to-end biosimilar network in Europe, spanning development through to commercial-scale manufacturing: 👉 The opening of our 𝗻𝗲𝘄 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗰𝗲𝗻𝘁𝗿𝗲 𝗶𝗻 𝗟𝗷𝘂𝗯𝗹𝗷𝗮𝗻𝗮 👉 The announcement of the investment in a 𝗻𝗲𝘄 𝗱𝗿𝘂𝗴 𝘀𝘂𝗯𝘀𝘁𝗮𝗻𝗰𝗲 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝘆 𝗶𝗻 𝗟𝗷𝘂𝗯𝗹𝗷𝗮𝗻𝗮, next to the development centre 👉 The opening of our 𝗵𝗶𝗴𝗵-𝘁𝗲𝗰𝗵 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗱𝗿𝘂𝗴 𝘀𝘂𝗯𝘀𝘁𝗮𝗻𝗰𝗲 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗰𝗲𝗻𝘁𝗿𝗲 𝗶𝗻 𝗟𝗲𝗻𝗱𝗮𝘃𝗮 This is a major step forward in delivering our Bio100 ambition: building a portfolio of more than 100 biosimilar medicines by 2040. Expanding access to biosimilars requires more than scientific expertise. It requires sustained commitment, long-term investment and the manufacturing capabilities needed to deliver reliable supply at scale. By strengthening our in-house development and manufacturing network, we are building greater flexibility, resilience and capacity to meet growing global demand for biosimilar medicines. Global Biosimilars Week is a reminder that the value of biosimilars is created years before patients receive treatment. Through investments we are laying the foundations to expand access to high-quality biosimilar medicines and bring the Bio100 ambition closer to reality. #GlobalBiosimilarsWeek

Realising the full value of biosimilars requires progress across many fronts, ranging from removing unnecessary commercial and IP barriers to ensuring public trust. One critical area is the regulatory framework for biosimilar approvals. We have seen a lot of progress in recent years, most importantly the recent steps by leading global regulators to promote the concept of biosimilar ‘streamlining’: the elimination of unnecessary large-scale clinical trials, a move that promises to significantly reduce both time and cost to market for future biosimilars. This is great news for patients and healthcare systems worldwide. However, as with so many things, it will be all about the implementation. At Sandoz, we are hopeful that regulatory authorities will now deliver in practice the way they have already done in theory. There is real momentum. Now we all have to build on it. 🎥 Find out why regulatory streamlining matters and how it can help accelerate access to biosimilar medicines worldwide. #GlobalBiosimilarsWeek

Behind every conversation about access is a person. For people like Cheryl, living with a chronic condition, access means having treatment options that are available and affordable. That is why competition matters. We need to reward innovation while enabling access to medicines. Cheryl continues to support informed, evidence-based conversations about access to medicines. Watch her story: https://lnkd.in/e-Tkn38X